TVAV-008
Phase 3Small molecule
TVAV-008 is one of 46 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
71 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Hepsera
GileadApproved
PEG-Intron
Merck & Co.Phase 3
Emtriva
GileadApproved
PEGASYS
Ppharmaand GmbH
Approved
Opdivo
Bristol-Myers SquibbPhase 2
Pegylated Interferon Alfa
Merck & Co.Phase 3
NA Therapy
GSKPhase 3
AHB-137
AAusper Biopharma Co., Ltd.
Phase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Azvudine
HHenan Genuine Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis1 trial
Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B
Not yet recruiting·GGrand Theravac Life Sciences (Nanjing) Co., Ltd.·Phase 3·NCT07282249·630 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TVAV-008. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details